Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
ScientificWorldJournal ; 2014: 641723, 2014.
Article in English | MEDLINE | ID: mdl-25386609

ABSTRACT

OBJECTIVE: A new, novel product, Cynatine HNS, was evaluated for its effects as a supplement for improving various aspects of hair and nails in a randomized, double-blind, placebo-controlled clinical trial. METHODS: A total of 50 females were included and randomized into two groups. The active group (n = 25) received 2 capsules containing Cynatine HNS, comprised of Cynatine brand keratin (500 mg) plus vitamins and minerals, per day, and the placebo group (n = 25) received 2 identical capsules of maltodextrin per day for 90 days. End points for hair loss, hair growth, hair strength, amino acid composition, and hair luster were measured. End points were also measured for nail strength and the appearance of nails. RESULTS: The results show that subjects taking Cynatine HNS showed statistically significant improvements in their hair and nails when compared to placebo. CONCLUSION: Cynatine HNS is an effective supplement for improving hair and nails in 90 days or less. EudraCT number is 2014-002645-22.


Subject(s)
Hair/chemistry , Hair/drug effects , Keratins/administration & dosage , Nails/chemistry , Nails/drug effects , Adult , Aged , Dietary Supplements , Double-Blind Method , Female , Hair/pathology , Humans , Keratins/chemistry , Keratins/metabolism , Middle Aged , Minerals/administration & dosage , Nails/pathology , Vitamins/administration & dosage
2.
J Diet Suppl ; 10(3): 184-94, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23927594

ABSTRACT

OBJECTIVE: A novel product Cynatine® FLX was evaluated on symptoms associated with knee osteoarthritis in a randomized, double-blind, placebo-controlled clinical trial. METHODS: A total of 50 males and females were included and randomized into two groups. The active group (n = 25) received two capsules totaling 500 mg of Cynatine® FLX per day and the placebo group (n = 25) received an identical two capsules of maltodextrin per day for 60 days. The WOMAC® Osteoarthritis Index, SF-36, and Lequesne Index of Severity were used to evaluate the symptoms. RESULTS: The results show that Cynatine® FLX was twice as effective in reducing pain scores as compared to placebo. Cynatine® FLX showed the same effectiveness in reducing stiffness. CONCLUSION: This new product may be effective in relieving symptoms of knee osteoarthritis.


Subject(s)
Biological Products/therapeutic use , Keratins/therapeutic use , Musculoskeletal Pain/drug therapy , Osteoarthritis, Knee/drug therapy , Adult , Aged , Animals , Biological Products/pharmacology , Double-Blind Method , Female , Humans , Keratins/pharmacology , Male , Middle Aged , Musculoskeletal Pain/etiology , Osteoarthritis, Knee/complications , Range of Motion, Articular/drug effects , Severity of Illness Index , Sheep , Wool/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...